Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01656148 (ClinicalTrials.gov)	June 2012	31/7/2012	FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Multiple Sclerosis	Drug: Fampridine -SR	University of Southern Denmark	Region of Southern Denmark;Biogen	Completed	18 Years	60 Years	All	108	Phase 4	Denmark
2	NCT01235221 (ClinicalTrials.gov)	December 2010	4/11/2010	Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.	Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials	Multiple Sclerosis	Drug: BIIB041 (Fampridine-SR)	Biogen Idec	Acorda Therapeutics	Completed	18 Years	70 Years	Both	38	Phase 3	Canada
3	NCT00649792 (ClinicalTrials.gov)	August 2007	28/3/2008	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial	Multiple Sclerosis	Drug: Fampridine -SR	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	214	Phase 3	United States;Canada
4	NCT00483652 (ClinicalTrials.gov)	May 2007	6/6/2007	Study of Fampridine-SR Tablets in Multiple Sclerosis Patients	Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine -SR;Drug: Placebo	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	240	Phase 3	United States;Canada
5	NCT00648908 (ClinicalTrials.gov)	June 2006	28/3/2008	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial	Multiple Sclerosis	Drug: Fampridine -SR	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	269	Phase 3	United States;Canada
6	NCT00127530 (ClinicalTrials.gov)	May 2005	4/8/2005	Study of Oral Fampridine-SR in Multiple Sclerosis	Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine -SR;Drug: Placebo	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	300	Phase 3	United States;Canada
7	NCT00654927 (ClinicalTrials.gov)	November 2003	4/4/2008	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine -SR b.i.d. (Twice Daily)	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	177	Phase 3	United States;Canada
8	NCT00053417 (ClinicalTrials.gov)	February 2003	29/1/2003	Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Placebo;Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP);Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP);Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	206	Phase 2	United States;Canada

先頭へ